Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Zealand Pharma to participate in upcoming investor conferences in March 2026
Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming…
Stocks making the biggest moves midday: Chevron, Hims and Hers, Xenon Pharma, Vertiv and more
Check out some of the companies making the biggest midday moves: Oil stocks – Oil stocks briefly traded higher as the commodity surged as the Iran War showed no sign of abating. U.S. crude briefly topped $110 per barrel overnight, hitting…
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
Issued on behalf of Cybin D/B/A Helus Pharma VANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory…
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $3,165,350.10 in Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $30.30…
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 94,124 Shares of Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 94,124 shares of the company's stock in a transaction on Friday, March 6th. The stock was sold at an average price of $30.32, for a total…
Johannes Jacob Piete Kastelein Sells 101,409 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 101,409 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $30.29, for a…
Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of 'Moderate Buy' from Brokerages
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has earned a consensus rating of 'Moderate Buy' from the eighteen ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell…
Second morning-after pill now available over the counter in Japan
Alinamin Pharmaceutical on Monday began selling emergency contraceptives to help protect against unintended pregnancies, the second such product to become available over the counter (OTC) in Japan. Lesoeru 72, which is priced at ¥6,930 ($44)…
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1054 ET – Roche Holding's giredestrant, a high-profile drug candidate for breast cancer, didn't meet the…
Supreme Novices' Hurdle odds: Latest prices & betting guide
The Supreme Novices' Hurdle is the traditional opening race of the Cheltenham Festival and is one of the most prestigious novice hurdles in National Hunt racing, with famed winners including Constitution Hill and 2025 victor Kopek Des Bordes. This…
Stock Market Today March 9, 2026: Sensex tanks 1,353 points
The Indian stock market witnessed a significant plunge in Sensex and Nifty, driven by soaring crude oil prices, escalating geopolitical tensions, and continuous foreign fund outflows, impacting investor sentiment. The Sensex and Nifty indices…
LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations
LabVantage Solutions, Inc., a global provider of laboratory informatics solutions and services, today announced the launch of LabVantage CORTEX, a next-generation artificial intelligence (AI), analytics, and automation platform. The launch…
Vect-Horus appoints Claudia Fromond as new Director of R&D
Senior biotech leader with extensive experience overseeing R&D strategy in immuno-oncology and immune-mediated diseases Proven track record leading first-in-class programs from discovery to early clinical development Appointment further strengthens…
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
Pratteln, Switzerland, March 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Marc Clausse as Chief Commercial Officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will retire after 11 years…
American Century Small Cap Value Fund Q4 2025 Commentary
The financials overweight is maintained due to positive net interest income trends and undervalued, high-quality banks, suggesting potential for continued outperformance as credit cycle fears appear overstated. Health care underweight is due to…
Receive a Daily briefing on Pharma Industry News
Get Started